[HTML][HTML] Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in …
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - npj Vaccines, 2020 - nature.com
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial …
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - NPJ …, 2020 - europepmc.org
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial …
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - 2020 - cabidigitallibrary.org
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
[HTML][HTML] Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in …
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - NPJ …, 2020 - ncbi.nlm.nih.gov
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
[PDF][PDF] Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in …
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - scienceopen.com
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.
A Blank, K Fürle, A Jäschke, G Mikus… - NPJ …, 2020 - search.ebscohost.com
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
B Antje, F Kristin, J Anja, M Gerd, M Lehmann… - NPJ …, 2020 - search.proquest.com
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
A Blank, K Fürle, A Jäschke, G Mikus, M Lehmann… - 2020 - katalog.ub.uni-heidelberg.de
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
A Blank, K Fürle, A Jäschke, G Mikus… - NPJ …, 2020 - pubmed.ncbi.nlm.nih.gov
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
B Antje, F Kristin, J Anja, M Gerd, M Lehmann… - NPJ …, 2020 - search.proquest.com
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …